Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 2/20 | 0.61 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.59 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.56 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.56 |
| ▸ | ADRA1B | P35368 | 4/20 | 0.56 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.53 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.52 |
| ▸ | CA12 | O43570 | 1/20 | 0.48 |
| ▸ | CA1 | P00915 | 1/20 | 0.48 |
| ▸ | CA2 | P00918 | 1/20 | 0.48 |
| ▸ | CA9 | Q16790 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12265184 | 0.86 | OPRL1 (0.63) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL8187774 | 0.82 | ADRA1D (0.58) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL27796310 | 0.81 | OPRM1 (0.71) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL11602963 | 0.81 | OPRM1 (0.70) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL7664626 | 0.81 | OPRM1 (0.66) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL7840973 | 0.81 | OPRM1 (0.66) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL11602782 | 0.81 | OPRM1 (0.66) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL10795357 | 0.81 | OPRM1 (0.66) | OPRM1OPRD1ADRA1DADRA1AADRA1B | |
| SCHEMBL11749081 | 0.80 | CYP2D6 (0.57) | OPRM1OPRD1ADRA1AHRH3OPRL1 | |
| SCHEMBL6891511 | 0.80 | OPRM1 (0.69) | OPRM1OPRD1ADRA1DADRA1AADRA1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1255738-B1 | GONADOTROPIN-RELEASING HORMONE RECEPTOR ANTAGONISTS AND METHODS RELATING THERETO | NEUROCRINE BIOSCIENCES INC (US) | 2012-03-07 | — | — | EP | disclosed |
| US-7462625-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2008-12-09 | — | — | US | disclosed |
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-09-06 | — | — | US | disclosed |
| US-7179815-B2 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | NEUROCRINE BIOSCIENCES, INC. (US) | 2007-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070208049-A1 | Gonadotropin-releasing hormone receptor antagonists and methods relating thereto | GNRHR, GHRHR, LHCGR | OPRM1 306/4885OPRD1 295/4885ADRA1D 351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.